newsfilter
← Latest News
GlobeNewswire·

Immatics Announces Second Quarter 2026 Financial Results and Business Update

Enrollment in the SUPRAME Phase 3 trial of anzu-cel (anzutresgene autoleucel, IMA203) remains on track to complete the required randomizations by year-end to support final analysis for the primary PFS endpoint;